Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops

Abstract

The emergence of low molecular weight kinase inhibitors as “targeted” drugs has led to remarkable advances in the treatment of cancer patients. The clinical benefits of these tumor therapies, however, vary widely in patient populations and with duration of treatment. Intrinsic and acquired resistance against such drugs limits their efficacy. In addition to the well studied mechanisms of resistance based upon drug transport and metabolism, genetic alterations in drug target structures and the activation of compensatory cell signaling have received recent attention. Adaptive responses can be triggered which counteract the initial dependence of tumor cells upon a particular signaling molecule and allow only a transient inhibition of tumor cell growth. These compensating signaling mechanisms are often based upon the relief of repression of regulatory feedback loops. They might involve cell autonomous, intracellular events or they can be mediated via the secretion of growth factor receptor ligands into the tumor microenvironment and signal induction in an auto- or paracrine fashion. The transcription factors Stat3 and Stat5 mediate the biological functions of cytokines, interleukins and growth factors and can be considered as endpoints of multiple signaling pathways. In normal cells this activation is transient and the Stat molecules return to their non-phosphorylated state within a short time period. In tumor cells the balance between activating and de-activating signals is disturbed resulting in the persistent activation of Stat3 or Stat5. The constant activation of Stat3 induces the expression of target genes, which cause the proliferation and survival of cancer cells, as well as their migration and invasive behavior. Activating components of the Jak-Stat pathway have been recognized as potentially valuable drug targets and important principles of compensatory signaling circuit induction during targeted drug treatment have been discovered in the context of kinase inhibition studies in HNSCC cells [1]. The treatment of HNSCC with a specific inhibitor of c-Src, initially resulted in reduced Stat3 and Stat5 activation and subsequently an arrest of cell proliferation and increased apoptosis. However, the inhibition of c-Src only caused a persistent inhibition of Stat5, whereas the inhibition of Stat3 was only transient. The activation of Stat3 was restored within a short time period in the presence of the c-Src inhibitor. This process is mediated through the suppression of P-Stat5 activity and the decrease in the expression of the Stat5 dependent target gene SOCS2, a negative regulator of Jak2. Jak2 activity is enhanced upon SOCS2 downregulation and causes the reactivation of Stat3. A similar observation has been made upon inhibition of Bmx, bone marrow kinase x-linked, activated in the murine glioma cell lines Tu-2449 and Tu-9648. Its inhibition resulted in a transient decrease of P-Stat3 and the induction of a compensatory Stat3 activation mechanism, possibly through the relief of negative feedback inhibition and Jak...

Metabolic tumor burden is associated with major oncogenomic alterations and serum tumor markers in patients with resected pancreatic cancer

“…It is well established that TP53, CDKN2A/p16, and SMAD4/DPC4 mutations occur during pancreatic carcinogenesis, but it is unknown whether these mutations are associated with the abnormal metabolic tumor burden detected by 18 F-FDG PET/CT. Nevertheless, abnormal expression profiles of TP53, CDKN2A/p16, and SMAD4/DPC4 are known to contribute to tumor malignancies and treatment-resistance [23][24][25][26][27]. Activation of transcription factor TP53 in response to a series of stimuli and stresses induces signaling pathways that affect anticancer mechanisms, including DNA repair, cell-cycle arrest and apoptosis.…”

Systemic QSAR and phenotypic virtual screening: chasing butterflies in drug discovery

“…For example, the inhibition of kinases by targeted drugs is evaded by compensatory changes in the signaling pathways of treated cancer cells [29]. Here, the signaling pathway activity of cancer cells inhibited by the targeted drug is restored or activated by alternative signaling components that elicit the same phenotypic consequences as the original pathway.…”

“…Here, the signaling pathway activity of cancer cells inhibited by the targeted drug is restored or activated by alternative signaling components that elicit the same phenotypic consequences as the original pathway. Other illustrative examples of signaling crosstalk and drug-mediated activation of compensatory pathways are provided in [29]. …”

Discovery of novel negletein derivatives as potent anticancer agents for acute myeloid leukemia

“…Acute myeloid leukemia (AML) as one of the leading causes of cancer deaths is characterized by rapid growth of abnormal white blood cells . For most of the patients with AML, traditional targeted anticancer therapies might eventually result in drug resistance due to compensatory crosstalk of various abnormal signal pathways . Natural products with diverse biological characteristics have been explored as invaluable sources for drug design with particular effectiveness in cancerous and infectious diseases .…”